

Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock

Inaugural-Dissertation
zur Erlangung des Doktorgrades
der Hohen Medizinischen Fakultät
der Rheinischen Friedrich-Wilhelms-Universität
Bonn

Andreas Hohn
aus Adenau

2013

Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock

Inaugural-Dissertation
zur Erlangung des Doktorgrades
der Hohen Medizinischen Fakultät
der Rheinischen Friedrich-Wilhelms-Universität
Bonn

Andreas Hohn
aus Adenau

2013

Angefertigt mit Genehmigung der
Medizinischen Fakultät der Universität Bonn

Gutachter: Herr Prof. Dr. med. Stefan Schröder
Gutachter: Herr Prof. Dr. med. Jörg Kalff

Tag der Mündlichen Prüfung: 27. August 2013

Aus der Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin
Direktor: Herr Prof. Dr. med. Andreas Hoeft

Für meine Eltern

„Zwei Dinge sollen Kinder von ihren Eltern bekommen: Wurzeln und Flügel“

Johann Wolfgang von Goethe

Inhaltsverzeichnis	Seite
1. Deutsche Zusammenfassung	6
Einleitung	6
Patienten und Methoden	7
Ergebnisse	7
Diskussion	9
Literaturverzeichnis der deutschen Zusammenfassung	11
2. Wissenschaftliche Veröffentlichung	14
Abstract	14
Background	15
Methods	15
Results	16
Discussion	19
Conclusion	20
References	21
3. Danksagung	23

1. Deutsche Zusammenfassung

Entwicklung der antibiotischen Therapiedauer bei Patienten mit schwerer Sepsis und septischen Schock nach Implementierung eines Procalcitonin-basierten Algorithmus

Einleitung

Während der frühzeitige Beginn einer antibiotischen Therapie bei schwerer Sepsis unbestritten ist (Kumar et al., 2006), ist die Dauer der antimikrobiellen Therapie in der klinischen Praxis jedoch weniger genau definiert und wird häufig nach den Erfahrungswerten der behandelnden Ärzte durchgeführt.

Dabei scheint aber die Verkürzung der antibiotischen Therapie eine wichtige Maßnahme zur Reduzierung von Antibiotikaresistenzen zu sein (Rice 2008), und in verschiedenen Arbeiten konnte gezeigt werden, dass eine solche Verkürzung bei schweren Atemwegsinfektionen sicher und effektiv durchgeführt werden konnte (Chastre et al., 2003; Micek et al., 2004; Singh et al., 2000). In diesem Zusammenhang bestehen zunehmende Hinweise, dass der Biomarker Procalcitonin (PCT) die klinische Entscheidung zur Beendigung einer Antibiotikatherapie bei unterschiedlichen Patientenkollektiven unterstützen kann (Bouadma et al., 2010; Briel et al., 2008; Christ-Crain et al., 2006; Hochreiter et al., 2009; Nobre et al., 2008; Schroeder et al., 2009; Schuetz et al., 2009; Stolz et al., 2009). Kürzlich erschienene Metaanalysen kamen zu dem Schluss, dass solche Algorithmen sicher sind, den Antibiotikaverbrauch senken und möglicherweise das Outcome verbessern können (Kopterides et al., 2010; Schuetz et al., 2012a; Tang et al., 2009). Für Patienten mit tiefen Atemwegsinfektionen zeigte eine aktuelle Chochrane-Analyse, dass unter PCT-Algorithmen eine signifikante Verkürzung der antibiotischen Therapiedauer ohne negative klinische Effekte erreicht werden konnte (Schuetz et al., 2012b).

Zwei Arbeiten bei Nicht-Intensivpatienten mit Atemwegsinfektionen konnten zeigen, dass die Anwendung einer PCT-gesteuerten antibiotischen Therapie auch außerhalb von Studienbedingungen effektiv ist (Albrich et al., 2012; Schuetz et al., 2010), jedoch liegen bisher keine Daten zur Anwendung an kritisch kranken Intensivpatienten unter Alltagsbedingungen vor.

In der vorliegenden Arbeit analysierten wir daher die Entwicklung der antibiotischen Therapiedauer bei chirurgischen Intensivpatienten mit schwerer Sepsis bzw. septischen Schock nach Einführung eines PCT-basierten Algorithmus in die klinische Praxis über einen fünfjährigen Zeitraum.

Patienten und Methoden

Die vorliegende Studie wurde von der Ethik-Kommission der Christian-Albrechts-Universität in Kiel begutachtet (D409/10). Aufgrund der retrospektiven Auswertung von klinischen, pseudonymisierten Routinedaten war keine Patienteneinwilligung erforderlich.

Im Jahr 2005 wurde auf der operativen Intensivstation im Westküstenklinikum Heide ein PCT-Algorithmus in die klinische Praxis implementiert.

Die PCT Messung erfolgte mit der täglichen Routine-Blutabnahme und die Antibiotikatherapie wurde dem Algorithmus folgend beendet, wenn:

1. die klinischen Zeichen einer Infektion abgeklungen waren und der PCT-Wert auf 1 ng/ml oder darunter abgefallen war, oder
2. bei einem PCT-Wert über 1 ng/ml ein Abfall auf 25 bis 35% des Ausgangswertes über drei Tage zu verzeichnen war.

Wir führten für erwachsene chirurgische Intensivpatienten zwischen 2005 und 2009 eine retrospektive Datenbankanalyse nach den Kriterien a) Sepsis und b) Organdysfunktion gemäß der Kriterien der ACCP/ SCCM (Bone et al., 1992) durch, so dass in unsere Analyse definitionsgemäß Patienten mit schwerer Sepsis und septischem Schock eingeschlossen wurden. Es wurden Daten für Alter, Geschlecht, Simplified Acute Physiology Score (SAPS) II, Acute Physiology And Chronic Health Evaluation (APACHE) Score II, Infektionsorte und Effektives Relativgewicht sowie für die primären Ergebnisparameter, *Dauer der Antibiotikatherapie auf der Intensivstation, Re-Infektionsrate, Beatmungsdauer, Intensivaufenthaltsdauer, 28 Tage-Mortalität und Antibiotikakosten* ausgewertet. Die Jahreswerte aus den demographischen und klinischen Daten wurden zunächst für stetige Merkmale mittels Varianzanalyse (ANOVA) und für kategoriale Merkmale mit logistischer Regression auf Unterschiede getestet. Anschließend erfolgte durch polynomiale Kontrastanalyse (bei stetigen Parametern) oder Cochran-Armitage Tests (bei kategorialen Parametern) eine Überprüfung auf lineare Trends über den Studienzeitraum. Im letzten Schritt wurden die primären Ergebnisparameter in einer Kovarianzanalyse (ANCOVA) bzw. logistischer Regression adjustiert für die Kovariaten, Alter, Geschlecht, SAPS II, APACHE II und effektives Relativgewicht auf lineare Trends getestet. Ein p-Wert kleiner 0,05 wurde hierbei als signifikant betrachtet.

Ergebnisse

Zwischen 2005 und 2009 wurden 146 Patienten mit schwerer Sepsis, bzw. septischem Schock identifiziert. Fünf Patienten mussten bei unvollständigem Datensatz aus der Analyse ausgeschlossen werden, sodass die Auswertung für 141 Patienten erfolgte.

Für die Merkmale Alter, Geschlecht, SAPS II, Effektives Relativgewicht und die Verteilung der Infektionsorte konnten über die Jahre keine signifikanten Unterschiede gefunden werden.

Lediglich für den APACHE II Score zeigte sich ein signifikanter Trend zu niedrigeren Werten über die Jahre (Tabelle 1). Ein ebenfalls signifikanter Trend war für eine Zunahme der PCT-Messungen pro Patient im Jahresvergleich zu erkennen.

Bei den Ergebnissen für die adjustierten Ergebnisparameter zeigte sich für die Dauer der Antibiotikatherapie eine durchschnittliche jährliche Abnahme um 1 Tag pro Jahr ($p = 0,02$) von $14,3 \pm 1,2$ Tagen in 2005 auf $9,0 \pm 1,7$ Tage in 2009. Die Re-Infektionsrate war durchschnittlich um 35,1% jährlich rückläufig ($p = 0,014$) und die Liegedauer durchschnittlich um 2,7 Tage pro Jahr regredient ($p < 0,001$). Ebenso war die Beatmungsdauer durchschnittlich um 42 Stunden jährlich über den Untersuchungszeitraum verkürzt ($p = 0,008$). Trends für eine reduzierte 28 Tage-Mortalität (22,4% pro Jahr) und geringere Kosten für Antibiotika (durchschnittlich 14,3 Euro jährlich) waren statistisch nicht signifikant (Tabelle 1).

Tab. 1: Demographische und klinische Daten, Primäre Ergebnisparameter								
Jahr	2005	2006	2007	2008	2009	p-Wert [§]	p-Wert Trend [#]	
Patienten (n)	38	31	27	27	18			
Geschlecht (m/w)	20/18	16/15	14/13	18/9	11/7	0,728	0,289	
Alter (Jahre)*	68,6 ±15,9	73,8 ±9,5	68,0 ±13,5	67,5 ±13,9	65,4 ±11,6	0,196	0,125	
SAPS II *	45,0 ±17,7	43,4 ±17,9	42,5 ±19,8	44,3 ±19,0	37,0 ±10,9	0,603	0,177	
Apache II *	20,0 ±8,8	20,5 ±8,8	18,2 ±8,7	17,9 ±9,7	15,6 ±7,2	0,327	0,041	
Eff. Relativgewicht*	14,8 ±1,6	13,3 ±11,4	17,2 ±14,0	14,5 ±13,6	19,2 ±18,5	0,623	0,256	
						Durchschnittliche jährliche Änderung		
						Mittelwert	95% CI	p-Wert
Intensivliegedauer (Tage)	26,0 ±1,9	19,5 ±2,2	18,5 ±2,3	16,3 ±2,3	15,8 ±2,8	-2,7	-4,1 bis -1,3	<0,001
Beatmungsdauer (Stunden)	571,4 ±41,5	455,0 ±47,3	404,1 ±49,2	362,0 ±49,9	467,9 ±60,9	-42,0	-72,6 bis -11,4	0,008
Antibiotikatherapie (Tage)	14,3 ±1,2	12,0 ±1,3	13,8 ±1,4	12,1 ±1,4	9,0 ±1,7	-1,0	-1,9 bis -0,2	0,020
Antibiotikakosten (Euro/Patient)	407,6 ±57,2	420,7 ±66,7	426,6 ±67,7	393,2 ±68,5	373,9 ±83,7	-14,3	-55,7 bis 27,1	0,495
Reinfektionsrate (anteilig)	0,31 ±0,07	0,37 ±0,08	0,13 ±0,06	0,12 ±0,06	0,08 ±0,06	-35,1%	-53,9% bis -8,5%	0,014
28-Tage Mortalität (anteilig)	0,54 ±0,06	0,51 ±0,07	0,55 ±0,08	0,48 ±0,07	0,34 ±0,01	-22,4%	-44,3% bis 8,1%	0,133
Demographische und klinische Daten (oberer Teil):								
* Mittelwert ± Standardabweichung.								
§ F-Test aus einer ANOVA oder Wald Chi ² -Test aus logistischer Regression.								
# Lineare polynome Kontraste oder Cochran-Armitage Trend-Test.								
SAPS II, Simplified Acute Physiology Score II								
APACHE II, Acute Physiology And Chronic Health Evaluation Score II								
Primäre Ergebnisparameter (unterer Teil):								
Adjustierte arithmetische Mittelwerte ± Standardfehler und jährliche Änderung der Ergebnisparameter mit 95-Konfidenzbereichsgrenzen (CI) und p-Werten aus den Trend-Tests aus Kovarianzanalysen (ANCOVA) oder logistischen Regressionsmodellen mit den Kovariaten Geschlecht, Alter, SAPS II, APACHE II, Effektives Relativgewicht								

Diskussion

Die Ergebnisse unserer Arbeit zeigen, dass nach Einführung eines PCT-Algorithmus in die klinische Praxis, die Antibiotikatherapiedauer bei Patienten mit schwerer Sepsis und septischem Schock außerhalb von Studienbedingungen zwischen 2005 und 2009 durchschnittlich um einen Tag pro Jahr von $14,3 \pm 1,2$ Tagen auf $9,0 \pm 1,7$ Tage reduziert werden konnte. Diese Reduktion hatte keine negativen Einflüsse auf das klinische und ökonomische Outcome.

Unsere Daten bestätigen somit die Ergebnisse aus verschiedenen Metaanalysen zur PCT-gesteuerten Antibiotikatherapie (Kopterides et al., 2010; Schuetz et al., 2012a; Tang et al., 2009). Die einzigen bisher auch außerhalb von Studienbedingungen vorliegenden Ergebnisse - allerdings bei Nicht-Intensivpatienten mit Atemwegsinfektionen - zeigen ebenfalls die Effektivität und Sicherheit einer antibiotischen Therapiesteuerung durch PCT-Algorithmen in der klinischen Routine unter Alltagsbedingungen (Albrich et al., 2012; Schuetz et al., 2010).

Die Einführung und vor allem die konsequente Umsetzung von standardisierten Abläufen und Algorithmen in der Intensivmedizin ist komplex, zeitaufwendig und bedarf multiprofessioneller Teamarbeit. In einer großen deutschen Querschnitterhebung konnte die Diskrepanz zwischen der Selbsteinschätzung und der tatsächlichen Umsetzung von Leitlinien demonstriert werden (Brunkhorst et al., 2008). Selbst in verschiedenen randomisierten kontrollierten Studien konnte gezeigt werden, dass die Studienteilnehmer bei 16 bis 53% der Patienten entgegen dem PCT-Algorithmus die antibiotische Therapie fortsetzten (Bouadma et al., 2010; Nobre et al., 2008; Stolz et al., 2009). Und auch unter realen klinischen Bedingungen nahm die Anwendungstreue mit zunehmender Krankheitsschwere ab (Albrich et al., 2012). In unserer Arbeit wurden zwar keine Daten zur Anwendungstreue des Algorithmus erhoben, aber möglicherweise deutet eine zunehmende Anzahl von PCT-Messungen pro Patient über die Jahre auf eine wachsende Akzeptanz des Algorithmus hin. Weitere Untersuchungen sollten die Anwendungstreue von solchen Algorithmen bei kritisch kranken Patienten außerhalb von Studienbedingungen untersuchen.

Die deutliche Senkung der Mortalität und die Reduktion der Beatmungsdauer oder der Rückgang der Re-Infektionsrate können nicht ausschließlich durch Implementierung des PCT-Algorithmus erklärt werden. Möglicherweise hatten die zunehmende Umsetzung der in 2004 publizierten Sepsis-Leitlinien (Dellinger et al., 2004) oder die Umsetzung eines lokalen Antibiotic-Stewardship-Programms positive Effekte auf die primären Ergebnisparameter. Die Einflüsse dieser oder anderer während der Studienphase umgesetzter Maßnahmen können trotz einer Adjustierung der Daten statisch nicht ausgeschlossen werden.

Eine endgültige Bewertung der Kosteneffektivität einer antibiotischen Therapiedauersteuerung durch einen PCT-Algorithmus ist mit dem vorliegenden Studiendesign nicht möglich. Wir

konnten zwar einen nicht signifikanten Trend zu geringeren Antibiotikakosten zeigen, jedoch ist die Betrachtung der Kosteneffektivität eines neu eingeführten Prozesses deutlich komplexer. Neben den Kosten für die zusätzlichen Laboruntersuchungen müsste beispielsweise auch ein Mehraufwand für Schulungsmaßnahmen berücksichtigt werden. Und neben einer potentiellen Einsparung von Antibiotika sind mögliche Reduktionen von Arzneimittel-induzierten Nebenwirkungen oder rückläufige Resistenzraten deutlich schwieriger zu quantifizieren. Auch eine eventuelle Kapazitätserhöhung mit vermehrter Intensivbelegung durch eine Verkürzung der Liegedauer spielt eine wichtige Rolle bei der Abschätzung der Kosteneffektivität. Auch hier sind weitere Untersuchungen notwendig.

Eine wesentliche Limitation unserer Untersuchung ist das Fehlen einer klassischen Kontrollgruppe. Somit kann der Umfang des Einflusses des implementierten Algorithmus auf die antibiotische Therapiedauer und die anderen Ergebnisparameter nicht abschließend bewertet werden. Dennoch können die Daten aus 2005, als der Algorithmus in die klinische Praxis eingeführt wurde und die Anzahl der PCT-Bestimmungen pro Patient noch gering war, als eine Art Kontrollgruppe betrachtet werden.

Insgesamt scheint die Anzahl an Patienten mit schwerer Sepsis (3,4%) in unserer Arbeit im Vergleich zu der Prävalenzstudie, die für deutsche Intensivstationen eine Prävalenz von etwa 11% angibt, eher gering (Engel et al., 2007). Der hohe Anteil an postoperativen Überwachungspatienten auf der untersuchten Intensivstation könnte eventuell die Prävalenz gesenkt haben. Zudem hängt eine retrospektive Datenerhebung immer von der Qualität der primären Dokumentation ab, so dass hierdurch möglicherweise nicht alle Patienten mit schwerer Sepsis oder septischem Schock identifiziert wurden und einer Auswertung entgangen sind. Eine höhere Anzahl an Patienten in der Auswertung hätte die Aussagekraft der Studie möglicherweise erhöht.

Schlussfolgerung

Dies ist die erste Studie, die die Effekte der Implementierung eines PCT-Algorithmus auf den Antibiotikaverbrauch unter klinischen Alltagsbedingungen bei septischen Intensivpatienten untersucht hat. Die Einführung des PCT-Protokolls war in dem untersuchten Fünfjahreszeitraum mit einer signifikanten Verkürzung der Antibiotikatherapiedauer assoziiert. Diese Verkürzung hatte keinen negativen Einfluss auf klinische (Mortalität, Beatmungsdauer, Intensivliegedauer und Re-Infektionsrate) oder ökonomische (Antibiotikakosten) Parameter. Diese Daten bestätigen die Ergebnisse aus prospektiven randomisierten Untersuchungen an kritisch Kranken und aus retrospektiven Erhebungen bei Nicht-Intensivpatienten. Weitere Studien zur Anwendungstreue von PCT-Protokollen unter klinischen Alltagsbedingungen und zum Einfluss auf Resistenzraten sowie zur Kosteneffektivität sollten folgen.

Literaturverzeichnis

Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, Bassetti S, Sprenger M, Bachli E, Sigrist T, Schwietert M, Amin D, Hausfater P, Carre E, Gaillat J, Schuetz P, Regez K, Bossart R, Schild U, Mueller B, Proreal Study Team FT. Effectiveness and Safety of Procalcitonin-Guided Antibiotic Therapy in Lower Respiratory Tract Infections in "Real Life": An International, Multicenter Poststudy Survey (ProREAL). *Arch Intern Med* 2012; 172: 715-722

Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 1992; 101: 1644-1655

Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Regnier B, Brun-Buisson C, Chastre J, Wolff M. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. *Lancet* 2010; 375: 463-474

Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, Periat P, Bucher HC, Christ-Crain M. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. *Arch Intern Med* 2008; 168: 2000-2007; discussion 2007-2008

Brunkhorst FM, Engel C, Ragaller M, Welte T, Rossaint R, Gerlach H, Mayer K, John S, Stuber F, Weiler N, Oppert M, Moerer O, Bogatsch H, Reinhart K, Loeffler M, Hartog C. Practice and perception--a nationwide survey of therapy habits in sepsis. *Crit Care Med* 2008; 36: 2719-2725

Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. *JAMA* 2003; 290: 2588-2598

Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Muller B. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. *Am J Respir Crit Care Med* 2006; 174: 84-93

Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. *Crit Care Med* 2004; 32: 858-873

Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K. Epidemiology of sepsis in

Germany: results from a national prospective multicenter study. *Intensive Care Med* 2007; 33: 606-618

Hochreiter M, Kohler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, Schroeder S. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. *Crit Care* 2009; 13: R83

Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. *Crit Care Med* 2010; 38: 2229-2241

Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit Care Med* 2006; 34: 1589-1596

Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. *Chest* 2004; 125: 1791-1799

Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. *Am J Respir Crit Care Med* 2008; 177: 498-505

Rice LB. The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile. *Clin Infect Dis* 2008; 46: 491-496

Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, von Spiegel T. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. *Langenbecks Arch Surg* 2009; 394: 221-226

Schuetz P, Batschwaroff M, Dusemund F, Albrich W, Burgi U, Maurer M, Brutsche M, Huber AR, Muller B. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. *Eur J Clin Microbiol Infect Dis* 2010; 29: 269-277

Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, Luyt CE, Chastre J, Tubach F, Kristoffersen KB, Wei L, Burkhardt O, Welte T, Schroeder S, Nobre V, Tamm M, Bhatnagar N, Bucher HC, Mueller B. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. *Clin Infect Dis* 2012a; 55: 651-662

Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. *JAMA* 2009; 302: 1059-1066

Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, Kristoffersen KB, Burkhardt O, Welte T, Schroeder S, Nobre V, Wei L, Bhatnagar N, Bucher HC, Briel M. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev* 2012b; 9: CD007498

Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. *Am J Respir Crit Care Med* 2000; 162: 505-511

Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Tamm M. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. *Eur Respir J* 2009; 34: 1364-1375

Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. *Infection* 2009; 37: 497-507

RESEARCH ARTICLE

Open Access

Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock

Andreas Hohn^{1*†}, Stefan Schroeder^{2†}, Anna Gehrt³, Kathrin Bernhardt³, Berthold Bein⁴, Karl Wegscheider⁵ and Marcel Hochreiter⁶

Abstract

Background: Procalcitonin (PCT)-protocols to guide antibiotic treatment in severe infections are known to be effective. But less is known about the long-term effects of such protocols on antibiotic consumption under real life conditions. This retrospective study analyses the effects on antibiotic use in patients with severe sepsis and septic shock after implementation of a PCT-protocol.

Methods: We conducted a retrospective ICU-database search for adult patients between 2005 and 2009 with sepsis and organ dysfunction who were treated accordingly to a PCT-guided algorithm as follows: Daily measurements of PCT (BRAHMS PCT LIA[®]; BRAHMS Aktiengesellschaft, Hennigsdorf, Germany). Antibiotic therapy was discontinued if 1) clinical signs and symptoms of infection improved and PCT decreased to ≤ 1 ng/ml, or 2) if the PCT value was >1 ng/ml, but had dropped to 25-35% of the initial value within three days. The primary outcome parameters were: antibiotic days on ICU, ICU re-infection rate, 28-day mortality rate, length of stay (LOS) in ICU, mean antibiotic costs (per patient) and ventilation hours. Data from 141 patients were included in our study. Primary outcome parameters were analysed using covariance analyses (ANCOVA) to control for effects by gender, age, SAPS II, APACHE II and effective cost weight.

Results: From baseline data of 2005, duration of antibiotic therapy was reduced by an average of 1.0 day per year from 14.3 ± 1.2 to 9.0 ± 1.7 days in 2009 ($p=0.02$). ICU re-infection rate was decreased by yearly 35.1% (95% CI -53 to -8.5 ; $p=0.014$) just as ventilation hours by 42 hours per year (95% CI -72.6 to -11.4 ; $p=0.008$). ICU-LOS was reduced by 2.7 days per year ($p<0.001$). Trends towards an average yearly reduction of 28-day mortality by -22.4% (95% CI -44.3 to 8.1 ; $p=0.133$) and mean cost for antibiotic therapy/ patient by -14.3 Euro (95% CI -55.7 to 27.1) did not reach statistical significance.

Conclusions: In a real-life clinical setting, implementation of a PCT-protocol was associated with a reduced duration of antibiotic therapy in septic ICU patients without compromising clinical or economical outcomes.

German clinical trials register: DRKS00003490

Keywords: Procalcitonin, Sepsis, Economical outcomes, Intensive care

* Correspondence: andreas.hohn@bergmannsheil.de

†Equal contributors

¹Department of Anaesthesiology, Intensive Care, Palliative Care and Pain Medicine, BG University Hospital Bergmannsheil, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, Bochum 44789, Germany

Full list of author information is available at the end of the article

Background

There is a dramatic increase in antibiotic-resistant infections [1-3], leading to higher mortality, longer hospital or intensive care unit (ICU) stays, and increased hospital costs [3,4]. While timely initiation of antibiotic therapy in patients with severe sepsis and septic shock is crucial and has been proven [5], length of antibiotic treatment in clinical practice often is decided by the attending clinician by means of his experience.

But, shortening the length of antibiotic courses seems to play an important role in reducing antibiotic resistance [6] and its effectiveness has been shown in several studies [7-9]. In this context, there is rising evidence that a procalcitonin (PCT)-based algorithm is a useful tool to support clinical decision when tailoring antibiotic therapy. Several randomised controlled trials in a variety of settings showed a reduction in antibiotic duration or an increase in antibiotic-free days. Clinical outcome either remained unaffected [10-15] or even was improved, as two studies revealed a reduction of length of stay (LOS) in the ICU [16,17]. Furthermore, recent meta-analyses concluded that PCT-guided antibiotic treatment appears to be safe, reduces antibiotic consumption and may also improve outcome [18-20]. In patients with acute respiratory infections, a current systematic Cochrane review revealed a significant reduction in duration of antibiotic treatment without negative effects on clinical outcome parameters [21].

Although the effectiveness of PCT-guided antibiotic therapy has been proven in several randomised clinical trials, so far less is known about implementation and effects of such protocols under out-of-study conditions. For patients with respiratory infections outside the ICU, two studies demonstrated that following a PCT algorithm significantly reduces antibiotic use without increasing the risk of complications [22,23]. But so far there is no study that evaluates the long-term effects of such an algorithm on antibiotic consumption in surgical ICU patients. Thus, in the present study we analyse the development of duration of antibiotic treatment in patients with severe sepsis in a surgical intensive care unit (ICU) over a five years period after implementation of a PCT-guided algorithm.

Methods

Patients and data collection

Ethics commission approval was obtained from the Medical Faculty at Christian Albrecht University of Kiel (D409/10) for our trial in the surgical intensive care ward at the West Coast Hospital in Heide. The informed consent was waived in view of the retrospective and anonymous nature of the study.

In 2005 we introduced a PCT-guided algorithm as follows: Daily measurements of PCT (BRAHMS PCT LIA[®]; BRAHMS Aktiengesellschaft, Hennigsdorf, Germany) with

the daily routine blood samples. Antibiotic therapy was discontinued if 1) clinical signs and symptoms of infection improved and PCT decreased to ≤ 1 ng/ml, or 2) if the PCT value was >1 ng/ml, but had dropped to 25-35% of the initial value within three days (Figure 1).


We conducted a retrospective ICU-database search for adult patients from our surgical ICU between 2005 and 2009 with a) sepsis and b) organ dysfunction on presentation as defined by the ACCP/SCCM Consensus Conference Committee [24] (i.e. gas exchange impairment (partial pressure of arterial oxygen (PaO_2)/fraction of inspired oxygen (FiO_2) < 300 mmHg), acute renal dysfunction (2-fold baseline creatinine increase or urine output < 0.5 ml/kg for at least two hours), platelet count below 100,000 cells/mm³, lactate blood concentration above 2 mmol/l or sepsis induced impaired mental status. Patients with sepsis induced mean arterial pressure below 65 mmHg for ≥ 1 hour despite adequate fluid resuscitation were classified as having septic shock).

Exclusion criteria were: age under 18 years; known pregnancy; bone-marrow transplant or patient undergoing chemotherapy; infections for which long-term antibiotic treatment is strongly recommended (e.g. infective endocarditis, tuberculosis, anterior mediastinitis after cardiac surgery) and do-not-resuscitate orders. Also, patients with an incomplete data set were excluded.

Data were collected for gender, age, Simplified Acute Physiology Score (SAPS) II, Acute Physiology And Chronic Health Evaluation (APACHE) Score II, German Diagnosis Related Groups (G-DRG)-effective cost weight and for the primary outcome parameters: antibiotic days on ICU, ICU re-infection rate, LOS in ICU, ventilation hours, 28-day mortality, and antibiotic costs per patient. Re-infection was defined as the growth of the initial causative bacterial strains, taken from the same infection site after ≥ 48 h of stopping antibiotics, in addition to clinical signs or symptoms of infection. Mean antibiotic costs per patient (Euro) were calculated by means of the hospital's wholesale prices without costs of administration.

Data analysis

Descriptive statistics are mean \pm standard deviation for patient characteristics or mean \pm standard error or 95% confidence intervals (CI) for outcome. Chi-squared test was employed for comparison of infection sites over the years. Number of PCT-measurements per patient for trend significance over the years was analysed with Kruskal-Wallis test. Annual means/ percentages of patient characteristics were first compared for any difference by analysis of variance (ANOVA) for continuous characteristics and by logistic regression for categorical characteristics. P values of the corresponding F tests and Wald chi-square tests are reported. In a second step, polynomial contrasts and Cochran-Armitage tests



were applied to test whether linear trends were to be observed in patient characteristics over the total study period. Since in observational studies of moderate size even non-significant imbalances may bias the results to a relevant extent, outcome analysis was exclusively performed by statistical control of the baseline characteristics. Thus, outcome parameters were tested for linear trends by analysis of covariance (ANCOVA) or logistic regression models with adjustment for the covariates gender, age, SAPS II, APACHE II and effective G-DRG cost weight. A $p < 0.05$ was considered statistically significant.

This method proves to be useful when a retrospective comparison between different treatment groups is performed as it compensates for imbalances in important prognostic variables, which may lead to biases in treatment effect, and additionally reduces the residual variability in the statistical models, thus increasing the precision of the estimates and the power of the applied statistical tests.

The statistical software package SPSS 15.0 (SPSS Inc., Chicago, IL, USA) and STATA 11.0 (STATA Corp LP,

College Station, TX, USA) were used for statistical analysis.

Results

Data of 4212 ICU-patients from 2005 to 2009 were screened. Through our data filter, we identified 146 patients with severe sepsis or septic shock. Of these, 5 patients were excluded from the study because of incomplete data set. In total, 141 patients were included in the final analysis set (Figure 2). Comparing the five years of study period, the number of patients, gender, age, SAPS II, APACHE II and effective cost weight fluctuated. However, no significant differences were observed ($p > 0.05$) with the exception of a linear trend in APACHE II towards lower means ($p = 0.041$) (Table 1). Over the years there was no significant difference between the infection sites (Table 2). For number of PCT measurements per patient, there was significant increasing trend from 2005 to 2009.

The adjusted analysis of 6 outcome parameters from baseline of 2005 revealed significant average yearly




Table 1 Demographic, clinical data and primary outcome parameters

Year	2005	2006	2007	2008	2009	p [§]	p-value trend [#]		
Patient (n)	38	31	27	27	18				
Gender (m/f)	20/18	16/15	14/13	18/9	11/7	0.728	0.289		
Age (years)*	68.6 ± 15.9	73.8 ± 9.5	68.0 ± 13.5	67.5 ± 13.9	65.4 ± 11.6	0.196	0.125		
SAPS II *	45.0 ± 17.7	43.4 ± 17.9	42.5 ± 19.8	44.3 ± 19.0	37.0 ± 10.9	0.603	0.177		
Apache II *	20.0 ± 8.8	20.5 ± 8.8	18.2 ± 8.7	17.9 ± 9.7	15.6 ± 7.2	0.327	0.041		
Effective cost weight *	14.8 ± 13.6	13.3 ± 11.4	17.2 ± 14.0	14.5 ± 13.6	19.2 ± 18.5	0.623	0.256		
							Average change per year		
							Mean	95% CI	p
ICU stay (days)	26.0 ± 1.9	19.5 ± 2.2	18.5 ± 2.3	16.3 ± 2.3	15.8 ± 2.8	-2.7	-4.1 to -1.3	< 0.001	
Ventilation (hours)	571.4 ± 41.5	455.0 ± 47.3	404.1 ± 49.2	362.0 ± 49.9	467.9 ± 60.9	-42.0	-72.6 to -11.4	0.008	
Antibiotic use (days)	14.3 ± 1.2	12.0 ± 1.3	13.8 ± 1.4	12.1 ± 1.4	9.0 ± 1.7	-1.0	-1.9 to -0.2	0.02	
Antibiotic costs (EUR/patient)	407.6 ± 57.2	420.7 ± 66.7	426.6 ± 67.7	393.2 ± 68.5	373.9 ± 83.7	-14.3	-55.7 to 27.1	0.495	
ICU reinfection rate (proportion)	0.31 ± 0.07	0.37 ± 0.08	0.13 ± 0.06	0.12 ± 0.06	0.08 ± 0.06	-35.1%	-53.9% to -8.5%	0.014	
28-day mortality (proportion)	0.54 ± 0.06	0.51 ± 0.07	0.55 ± 0.08	0.48 ± 0.07	0.34 ± 0.01	-22.4%	-44.3% to 8.1%	0.133	

Demographic and clinical data:

* Mean ± standard deviation.

[§] F test of ANOVA (continuous characteristic) or Wald chi square test (categorical characteristic) of logistic regression model.

[#] Linear polynomial contrasts (continuous characteristic) or Cochran-Armitage trend tests (categorical characteristic).

SAPS II, Simplified Acute Physiology Score II.

APACHE II, Acute Physiology And Chronic Health Evaluation Score II.

Primary outcome parameters:

Adjusted Means ± standard error and average yearly change of outcome parameters, with 95 confidence limits (CI) and p values of trend tests from ANCOVA or logistic regression models with covariates gender, age, SAPS II, APACHE II and effective cost weight.


Table 2 Sites of infection

	2005	2006	2007	2008	2009	p-value
Number of patients	38	31	27	27	18	
Pneumonia	21,1% (8)	12,9% (4)	29,6% (8)	22,2% (6)	33,3% (6)	n. s.
Abdominal	57,9% (22)	58,1% (18)	63,0% (17)	53,6% (15)	38,9% (7)	n. s.
Urogenital	2,6% (1)	3,2% (1)	3,7% (1)	3,7% (1)	-	n. s.
Soft tissue	-	6,5% (2)	-	-	11,1% (2)	n. s.
Others/ unknown	18,4% (7)	19,4% (6)	3,7% (1)	18,5% (5)	16,7% (3)	n. s.

n. s., not significant.

reductions in days on antibiotic therapy (1.0 day per year, $p = 0.02$) from 14.3 ± 1.2 to 9.0 ± 1.7 days, rate of re-infection on ICU (35.1% per year, $p = 0.014$), ICU-LOS (2.7 days per year, $p < 0.001$) and ventilation time (42 hours per year, $p = 0.008$). Trends towards reduction of 28-day mortality by 22.4% per year (95% confidence interval: -44.3% to 8.1%; $p = 0.133$) and total cost for

antibiotic therapy (14.3 Euro per patient and year, $p = 0.495$) per patient did not reach statistical significance (Table 1, Figure 3). Of the controlled covariates, effective cost weight had significant impact on all primary outcome parameters ($p < 0.001$). Effective cost weight represents the amount of reimbursement for the respective payment in the German Diagnosis Related Groups (G-DRG)



system. It reflects resource consumption and clinical complexity of the hospital patient population. Furthermore, case mix index (i. e. the total cost weights of all inpatients per a defined time period divided by the number of admissions) is a surrogate marker for average patients' clinical complexity and is correlated with antibiotic use in hospitals [25]. Age had significant impact on 28-day mortality ($p < 0.001$) whereas, for gender, SAPS II and APACHE II we found no significant impact on the primary outcome parameters.

Discussion

Antibiotic treatment

The results of the present study show that after implementation of a PCT-guided algorithm in 2005 length of antibiotic therapy in surgical patients with severe sepsis or septic shock was reduced by an average of 1.0 day per year from 14.3 ± 1.2 (2005) to 9.0 ± 1.7 days (2009). This reduction was associated with a significant reduction in ICU re-infection rate, ICU-LOS and ventilation hours and non-significant reduction of 28-day mortality and mean costs of antibiotics per patient. Thus, shortening antibiotic therapy did not have negative effects on clinical or economical outcome.

The length of antibiotic therapy was effectively reduced in several randomised controlled trials using PCT-guided algorithms. Thus, it was concluded that implementation of a PCT-based algorithm may reduce antibiotic exposure in critically ill, septic patients without compromising clinical outcomes [19]. Hence, our findings are in accordance with results from randomised controlled trials and further expand previous studies which confirmed the effectiveness of PCT-guided antibiotic treatment for non-ICU patients outside study conditions [22,23].

Algorithm adherence

However, little is known about transfer of such protocols into clinical practice and development of antibiotic use after implementation of a PCT-guided algorithm. Implementation of new protocols in an ICU is complex, multi-professional, and transfer to clinical practice and optimisation of adherence is time-consuming and develops over a long period. For example, variability in compliance with sepsis resuscitation bundles has recently been shown [26]. And in a large one-day cross-sectional survey in German ICUs a great discrepancy between perception of guideline-adherence and clinical practice was found [27]. Two studies outside the ICU revealed a high adherence to the PCT algorithm and confirmed results from RCTs with a shortened duration of antibiotic treatment [22,23]. But in one study, a decreased compliance to the algorithm with increasing severity of illness was found [22]. This is consistent with RCTs in ICU patients where physicians refused to stop

antibiotics despite the opposite suggestion of the PCT-algorithm in 16-53% [10,15,17]. In our analysis, adherence to the PCT-algorithm was not evaluated over the study period. But increasing average number of PCT-measurements per patient from 1.6 ± 4.5 in 2005 to 18.6 ± 16.4 in 2009, possibly indicates more acceptance of the PCT-protocol. Further studies are required to evaluate protocol-adherence in critically ill patients outside study conditions.

Re-infection rate

Interestingly, we found a yearly reduction of 35.1% in ICU re-infection rate. To our knowledge, so far, six randomised controlled trials assessed the utility of PCT in tailoring antibiotic therapy in septic ICU individuals [10,13,15-17,28]. Only Nobre and Bouadma provided data of the re-infection rate [10,17]. Nobre and colleagues included only a small number of patients ($n=79$) of a mixed ICU population and it remains unclear how many surgical patients were included. However, no differences in terms of re-infection rate in the PCT-group compared to the control group were found. Bouadma and colleagues showed in 621 septic ICU patients that a PCT-guided algorithm can reduce the days on antibiotic therapy. Shortening the therapy did not affect the re-infection rate. However, less than 10% of the population were surgical ICU patients. Our findings probably may be associated with effects from an antimicrobial stewardship program with local guidelines for initial empirical antibiotic treatment and routinely clinical rounds with an infectious diseases (ID) fellow.

Mortality and mechanical ventilation

Furthermore, an average yearly mortality reduction of 22.4% and decreased ventilation hours cannot be solely explained by implementation of a PCT algorithm. In 2004, sepsis guidelines for management of severe sepsis and septic shock were published and extensively implemented in clinical practice [29]. Impact of interventions from these guidelines or other implemented strategies during the study period cannot entirely be excluded in an observational study of such a long period, even if an extensive adjustment for covariates took place. However, although these international guidelines recommend a length of 7 to 10 days for antibiotic therapy in patients with severe sepsis, in two recent German multi-center studies, duration of antibiotic treatment was quite longer. In the VISEP study (2003 – 2005) [30], patients in the different study groups with a median stay of 13.5 to 16.0 days in the ICU had a median of zero antibiotic-free days. Similarly, also a median of zero antibiotic-free days was found in the MAXSEP study (2007 – 2010) [31] where patients had a median ICU-LOS of 12 days.

Antimicrobial stewardship

PCT-algorithms for guidance of antibiotic treatment may enhance adherence to guidelines since clinicians may be reassured in their decision to discontinue antibiotics by an objective parameter. It must be emphasised that PCT-algorithms are only a single component in strategies for optimising antibiotic treatment. Antimicrobial stewardship programs are important concepts for a more rational utilisation of antibiotics [32]. Most elements of antimicrobial stewardship programs focus on structural and professional improvements: educational programs, local guidelines for an appropriate initial choice of antibiotics, resistance statistics and strategies (e.g. clinical rounds with infectious diseases fellow) for streamlining and de-escalating antimicrobial therapy. In this context, integration of biomarker-guided antibiotic treatment into antibiotic stewardship programs appears to be essential [33].

Cost effectiveness

Our study revealed no significant antibiotic cost reduction. But there seems to be a trend to lower costs over the years. In our hospital, cost amounted to 14 Euros per PCT-test. But, a final assessment of cost effectiveness of a PCT-guided antibiotic therapy cannot be made with the present study design since there are numerous variables influencing clinical processes of care, many of which are difficult to quantify. For example, multi-resistant microorganisms significantly increase treatment expenses due to requirement of isolation procedures and use of costly reserve antibiotics. Shortening antibiotic treatment may have potential to reduce the incidence of multi-resistant microorganisms and therefore consequential costs. Also, possibly reduced incremental cost of antibiotic related adverse effects were not considered in our study. Furthermore, in times of shortage of ICU beds, a reduction in ICU-LOS leads to economical advantages. An average yearly reduction of 2.7 days in ICU-LOS like in our study has potential to conserve resources and enhance ICU capacity and thus may increase the hospital's refund. A previous study confirmed that under certain, assumptions managing antibiotic treatment with PCT-guided algorithms may reduce overall cost of care [34] and a data modelling analysis calculated possibly savings of € 1,163 for ICU-patients in the G-DRG system by guiding antibiotic treatment with a PCT-algorithm [35]. Nonetheless, the cost effectiveness of PCT-guided strategies needs to be fully evaluated in randomised controlled trials.

Antimicrobial resistance

Although antibiotic use has been reduced by PCT-guided strategies, a corresponding reduction in isolation of antibiotic-resistant organisms has not yet been

demonstrated [33]. Data for correlation between the reduced use of antibiotics and impact on a decrease in multi-resistant organisms were not obtained in our analysis and further studies are required to answer this question.

PCT algorithms

Numerous PCT-algorithms with different cut-off values for starting or discontinuing antibiotic therapy have been evaluated [10-12,14,16,17,28,36-39]. Most of these trials have shown the effectiveness of standardised algorithms to guide antibiotic therapy, even if the same algorithm was used for different causes of infection. In future, further studies are required to answer the question whether we need specific PCT-algorithms for numerous different causes of severe infection in surgical patients or whether it suffices to use a general PCT-algorithm to achieve a more judicious use of antibiotics.

Nonetheless, our data and the results of several studies and meta-analyses provide that PCT-guided algorithms seem to be a useful and safe tool in clinical practice to discontinue antibiotic treatment without negative effects on clinical or economical outcomes.

Limitations

The main shortcoming of our study is that we did not compare our results with data from a historical control group. Thus, it remains unclear to which extent reductions in antibiotic consumption and improvements in outcomes are exactly related to the PCT protocol. However, data from 2005, when the PCT-algorithm was implemented and number of PCT-measurements per patient was low, were used as baseline, showing how antibiotic use improved over the years when the program was transferred into clinical practice.

In our study 3.4% of all patients were reported to have severe sepsis whereas prevalence for severe sepsis including septic shock in Germany's ICUs is about 11% [40]. A retrospective search for patients with severe sepsis in our ICU database depends on quality of primary documentation and possibly not all eligible patients could be identified and included. This may explain the seemingly low number of patients detected with severe sepsis in our study. In addition, our ICU was also used for short-term postoperative and intermediate care and therefore the rate of patients with the highest risk for infections was probably low. Nevertheless, a higher total number of patients with severe sepsis probably would have increased the validity of our study.

Conclusions

This is the first study that analyses the long-term effects on antibiotic consumption after implementation of a PCT-guided algorithm to discontinue antibiotic treatment

under real-life clinical conditions in ICU-patients. In a real-life clinical setting, implementation of a PCT-protocol was associated with a reduced duration of antibiotic therapy in septic ICU patients without compromising clinical or economical outcomes. Further studies to assess the impact of PCT-protocols on reduction of resistant organisms are required. Also, algorithm-adherence and cost-effectiveness of a procalcitonin-guided strategy should be fully evaluated in a real-life setting of an ICU.

Abbreviations

ACCP: American college of chest physicians; ANCOVA: Analysis of covariance; ANOVA: Analysis of variance; APACHE: Acute physiology and chronic health evaluation score; CI: Confidence interval; FiO₂: Fraction of inspired oxygen; G-DRG: German diagnosis related group; ICU: Intensive care unit; LOS: Length of stay; PaO₂: Partial pressure of arterial oxygen; PCT: Procalcitonin; RCT: Randomised controlled trial; SAPS: Simplified acute physiology score; SCCM: Society of critical care medicine.

Competing interests

SS served as consultant and has received payments from BRAHMS AG for speaking engagements. KW has received funding from BRAHMS AG for performing the statistical analysis. All other authors declare no competing interests.

Authors' contribution

AH, SS and MH carried out data collection, contributed to the design of the study and drafted the manuscript. BB participated in the design of the study. KW participated in the design of the study, performed the statistical analysis and drafted the manuscript. AG and KB participated in the design of the study and data collection. All authors read and approved the final manuscript.

Author details

¹Department of Anaesthesiology, Intensive Care, Palliative Care and Pain Medicine, BG University Hospital Bergmannsheil, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, Bochum 44789, Germany. ²Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, Hospital Düren gem. GmbH, Roonstr. 30, Düren 52351, Germany. ³Department of Anaesthesiology and Intensive Care Medicine, West Coast Hospital, Esmarchstr. 50, Heide 25746, Germany. ⁴Department of Anaesthesiology and Intensive Care Medicine, University Hospital Schleswig-Holstein, Campus Kiel, Schwannenweg 21, Kiel 24105, Germany. ⁵Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany. ⁶Department of Anaesthesiology, University Hospital Heidelberg, Im Neuenheimer Feld 110, Heidelberg 69120, Germany.

Received: 27 September 2012 Accepted: 20 March 2013

Published: 1 April 2013

References

1. Rice LB: Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. *J Infect Dis* 2008, **197**(8):1079–1081.
2. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J Jr: The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. *Clin Infect Dis: an official publication of the Infectious Diseases Society of America* 2008, **46**(2):155–164.
3. Giske CG, Monnet DL, Cars O, Carmeli Y: Clinical and economic impact of common multidrug-resistant gram-negative bacilli. *Antimicrob Agents Chemother* 2008, **52**(3):813–821.
4. Slama TG: Gram-negative antibiotic resistance: there is a price to pay. *Crit Care* 2008, **12**(Suppl 4):S4.
5. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit Care Med* 2006, **34**(6):1589–1596.
6. Rice LB: The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile. *Clin Infect Dis: an official publication of the Infectious Diseases Society of America* 2008, **46**(4):491–496.
7. Micek ST, Ward S, Fraser VJ, Kollef MH: A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. *Chest* 2004, **125**(5):1791–1799.
8. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. *Am J Respir Crit Care Med* 2000, **162**(2 Pt 1):505–511.
9. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, et al: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. *JAMA* 2003, **290**(19):2588–2598.
10. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, et al: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. *Lancet* 2010, **375**(9713):463–474.
11. Briel M, Schuetz P, Mueller B, Young J, Schild U, Nusbaumer C, Periat P, Bucher HC, Christ-Crain M: Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. *Arch Intern Med* 2008, **168**(18):2000–2007. discussion 2007–2008.
12. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. *Am J Respir Crit Care Med* 2006, **174**(1):84–93.
13. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, Keck FS, von Spiegel T: Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. *Langenbeck's archives of surgery/Deutsche Gesellschaft für Chirurgie* 2009, **394**(2):221–226.
14. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, et al: Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. *JAMA* 2009, **302**(10):1059–1066.
15. Stolz D, Smyrniotis N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, et al: Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. *Eur Respir J: official journal of the European Society for Clinical Respiratory Physiology* 2009, **34**(6):1364–1375.
16. Hochreiter M, Kohler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, Schroeder S: Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. *Crit Care* 2009, **13**(3):R83.
17. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J: Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. *Am J Respir Crit Care Med* 2008, **177**(5):498–505.
18. Tang H, Huang T, Jing J, Shen H, Cui W: Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. *Infection* 2009, **37**(6):497–507.
19. Kopterides P, Siempos I, Tsangaris I, Tsantes A, Armaganidis A: Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. *Crit Care Med* 2010, **38**(11):2229–2241.
20. Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, Luyt CE, Chastre J, Tubach F, Kristoffersen KB, et al: Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. *Clin Infect Dis: an official publication of the Infectious Diseases Society of America* 2012, **55**(5):651–662.
21. Schuetz P, Müller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, et al: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane database of systematic reviews (Online)* 2012, **9**:CD007498.
22. Albrich WC, Dusemund F, Bucher B, Meyer S, Thomann R, Kuhn F, Bassetti S, Sprenger M, Bachli E, Sigris T, et al: Effectiveness and Safety of Procalcitonin-Guided Antibiotic Therapy in Lower Respiratory Tract Infections in "Real Life": An International, Multicenter Poststudy Survey (ProREAL). *Arch Intern Med* 2012, **172**(9):715–722.

23. Schuetz P, Batschwaroff M, Dusemund F, Albrich W, Burgi U, Maurer M, Brutsche M, Huber AR, Muller B: **Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey.** *Eur J Clin Microbiol Infect Dis: official publication of the European Society of Clinical Microbiology* 2010, **29**(3):269–277.
24. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: **Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.** *Crit Care Med* 1992, **20**(6):864–874.
25. Kuster SP, Ruef C, Bollinger AK, Ledergerber B, Hintermann A, Deplazes C, Neuber L, Weber R: **Correlation between case mix index and antibiotic use in hospitals.** *J Antimicrob Chemother* 2008, **62**(4):837–842.
26. Shiramizo SC, Marra AR, Durao MS, Paes AT, Edmond MB, Pavao dos Santos OF: **Decreasing mortality in severe sepsis and septic shock patients by implementing a sepsis bundle in a hospital setting.** *PLoS One* 2011, **6**(11):e26790.
27. Brunkhorst FM, Engel C, Ragaller M, Welte T, Rossaint R, Gerlach H, Mayer K, John S, Stuber F, Weiler N, et al: **Practice and perception—a nationwide survey of therapy habits in sepsis.** *Crit Care Med* 2008, **36**(10):2719–2725.
28. Jensen JU, Hein L, Lundgren B, Bestle MH, Mohr TT, Andersen MH, Thornberg KJ, Loken J, Steensen M, Fox Z, et al: **Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial.** *Crit Care Med* 2011, **39**(9):2048–2058.
29. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al: **Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.** *Crit Care Med* 2004, **32**(3):858–873.
30. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, et al: **Intensive insulin therapy and pentastarch resuscitation in severe sepsis.** *N Engl J Med* 2008, **358**(2):125–139.
31. Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C, Nierhaus A, Jaschinski U, Meier-Hellmann A, Weyland A, et al: **Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.** *JAMA* 2012, **307**(22):2390–2399.
32. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, et al: **Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.** *Clin Infect Dis: an official publication of the Infectious Diseases Society of America* 2007, **44**(2):159–177.
33. Hayashi Y, Paterson DL: **Strategies for reduction in duration of antibiotic use in hospitalized patients.** *Clin Infect Dis: an official publication of the Infectious Diseases Society of America* 2011, **52**(10):1232–1240.
34. Heyland DK, Johnson AP, Reynolds SC, Muscedere J: **Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation.** *Crit Care Med* 2011, **39**(7):1792–1799.
35. Wilke MH, Grube RF, Bodmann KF: **The use of a standardized PCT-algorithm reduces costs in Intensive Care in septic patients - A DRG-based simulation model.** *Eur J Med Res* 2011, **16**(12):543–548.
36. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B: **Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.** *Lancet* 2004, **363**(9409):600–607.
37. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M: **Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy.** *Chest* 2007, **131**(1):9–19.
38. Svoboda P, Kantorova I, Scheer P, Radvanova J, Radvan M: **Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery?** *Hepatogastroenterology* 2007, **54**(74):359–363.
39. Kristoffersen KB, Sogaard OS, Wejse C, Black FT, Greve T, Tarp B, Storgaard M, Sodemann M: **Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission—a randomized trial.** *Clin Microbiol Infect* 2009, **15**(5):481–487.
40. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, et al: **Epidemiology of sepsis in Germany: results from a national prospective multicenter study.** *Intensive Care Med* 2007, **33**(4):606–618.

doi:10.1186/1471-2334-13-158

Cite this article as: Hohn et al: Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. *BMC Infectious Diseases* 2013 **13**:158.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



3. Danksagung

Mein besonderer Dank gilt Herrn Professor Dr. med. Stefan Schröder, meinem Doktorvater, der durch sein unermüdliches Engagement dieses Projekt überhaupt erst möglich gemacht hat. In vielen konstruktiven Gesprächen nahm die Arbeit immer klarere Formen an und seine sorgfältigen und immer zügigen Korrekturen haben den Abschluss dieser Arbeit entscheidend vorangetrieben. Für diese Zusammenarbeit, die mir auch persönlich große Freude bereitet hat, und die hervorragende Betreuung möchte ich mich nochmals herzlich bedanken. Ich hoffe, auch zukünftig weiter mit Herrn Professor Schröder zusammen arbeiten zu können.

Weiterhin möchte ich der gesamten Arbeitsgruppe und ganz besonders Herrn Dr. med. Marcel Hochreiter für die zahlreichen konstruktiven Beiträge und die wertvollen Anregungen zum Gelingen des Projektes danken.

Nicht genug kann ich meiner Familie danken, die mir mit großem Verständnis die Zeit für diese Arbeit gegeben hat und an vielen Abenden und Wochenenden auf mich verzichten musste. Ohne eine solch wunderbare Familie im Rücken wäre das alles nicht möglich gewesen.